Oxidative Stress in Kawasaki Disease

Part of the Oxidative Stress in Applied Basic Research and Clinical Practice book series (OXISTRESS)


There exists a close association between inflammation and oxidative stress. Further, oxidative stress plays a role in the pathology of inflammation-based Kawasaki disease. An excessive in vivo production of reactive oxygen species results in oxidative stress load, which triggers a never-ending vicious spiral of inflammatory reactions and reactive oxygen metabolites. This forms the basis for acute stage Kawasaki disease. Kawasaki disease involves multiple intricately connected inflammatory reactions activated via a cytokine cascade. Features of Kawasaki disease suggest an infectious cause; however, this has not been clarified yet.

Although inflammation in the blood vessels and oxidative stress can be rapidly controlled by acute medical treatment, both conditions may persist and manifest in many forms over long periods. This has been identified in recent years as a problem in the chronic phase of Kawasaki disease. Further, both vascular inflammation and oxidative stress constantly inflict damage to the blood vessels, and are widely speculated to increase the risk of arteriosclerosis. The current discussion focuses on whether these features have implications in Kawasaki disease.


Reactive Oxygen Species Kawasaki Disease Excess Reactive Oxygen Species IVIG Treatment Kawasaki Disease Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Biological antioxidant potential


C-reactive protein


Endothelium-derived relaxing factor


Endothelial NO synthase


Endothelium-dependent vasodilation response




Inducible NO synthase


Intravenous immunoglobulin


Kawasaki disease


Nicotinamide adenine dinucleotide/nicotinamide adenine dinucleotide phosphate


Neutrophil elastase


Nuclear factor kappa B


Nitric oxide


Nitrogen oxides


Reactive oxygen metabolites


Reactive oxygen species


Thrombin-antithrombin complex


Tumor necrosis factor-α


  1. 1.
    Kawasaki T (1967) Acute febrile muco-cutaneous lymph node syndrome in young children with unique digital desquamation: clinical observation of 50 cases. Jpn J Allergol 16:178–222 (in Japanese)Google Scholar
  2. 2.
    Cave AC, Brewer AC, Narayanapanicker A, Ray R, Grieve DJ, Walker S, Shah AM (2006) NADPH oxidases in cardiovascular health and disease. Antioxid Redox Signal 8:691–728PubMedCrossRefGoogle Scholar
  3. 3.
    Sies H (1985) Oxidative stress: inductor remarks. In: Sies H (ed) Oxidative stress. Academic, London, pp 1–8CrossRefGoogle Scholar
  4. 4.
    Sies H (2000) What is oxidative stress? In: Kency JF Jr (ed) Oxidative stress and vascular disease. Kluwer Academic Publishers, Boston, pp 1–8CrossRefGoogle Scholar
  5. 5.
    Phan SH, Gannon DE, Varani J, Ryan US, Ward PA (1989) Xanthine oxidase activity in rat pulmonary artery endothelial cells and its alteration by activated neutrophils. Am J Pathol 134:1201–1211PubMedCentralPubMedGoogle Scholar
  6. 6.
    Furukawa S, Matsubara T, Jujoh K, Yone K, Sugawara T, Sasaki K, Kato H, Yabuta K (1988) Peripheral blood monocyte/macrophages and serum tumor necrosis factor in Kawasaki disease. Clin Immunol Immunopathol 48:247–251PubMedCrossRefGoogle Scholar
  7. 7.
    Furukawa S, Matsubara T, Yone K, Hirano Y, Okumura K, Yabuta K (1992) Kawasaki disease differs from anaphylactoid purpura and measles with regard to tumour necrosis factor-alpha and interleukin 6 in serum. Eur J Pediatr 151:44–47PubMedCrossRefGoogle Scholar
  8. 8.
    Lin CY, Lin CC, Hwang B, Chiang B (1992) Serial changes of serum interleukin-6, interleukin-8, and tumor necrosis factor alpha among patients with Kawasaki disease. J Pediatr 21:924–926CrossRefGoogle Scholar
  9. 9.
    Imano Y, Harada K, Okuni M, Kimoto K, Takeuchi S, Sakurabayashi I (1987) Immunoreactive polymorphonuclear leukocyte elastase in complex with alpha 1-antitrypsin in Kawasaki disease. Acta Paediatr Jpn 29:202–205CrossRefGoogle Scholar
  10. 10.
    Buttery LDK, Springall DR, Chester AH, Evans TJ, Standfield N, Parums DV, Yacoub MH, Polak JM (1996) Inducible nitric oxide synthase is present within human atherosclerotic lesions and promotes the formation and activity of peroxynitrite. Lab Invest 75:77–85PubMedGoogle Scholar
  11. 11.
    Yahata T, Suzuki C, Hamaoka A, Fujii M, Hamaoka K (2011) Dynamics of reactive oxygen metabolites and biological antioxidant potential in the acute stage of Kawasaki disease. Circ J 75:2453–2459PubMedCrossRefGoogle Scholar
  12. 12.
    JCS Joint Working Group (2010) Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease (JCS 2008)—digest version. Circ J 74:1989–2020CrossRefGoogle Scholar
  13. 13.
    Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T, Arakawa H, Kato T, Hara T, Hamaoka K, Ogawa S, Miura M, Nomura Y, Fuse S, Ichida F, Seki M, Fukazawa R, Ogawa C, Furuno K, Tokunaga H, Takatsuki S, Hara S, Morikawa A (2012) RAISE study group investigators. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomized, open-label, blinded-endpoints trial. Lancet 28:1613–1620CrossRefGoogle Scholar
  14. 14.
    Weiss JE, Eberhard BA, Chowdhury D, Gottlieb BS (2004) Infliximab as a novel therapy for refractory Kawasaki disease. J Rheumatol 31:808–810PubMedGoogle Scholar
  15. 15.
    Burns JC, Mason WH, Hauger SB, Janai H, Bastian JF, Wohrley JD, Balfour I, Shen CA, Michel ED, Shulman ST, Melish ME (2005) Infliximab treatment for refractory Kawasaki disease. J Pediatr 146:662–667PubMedCrossRefGoogle Scholar
  16. 16.
    Sugimura T, Kato H, Inoue O, Fukuda T, Sato N, Ishii M, Takagi J, Akagi T, Maeno Y, Kawano T (1994) Intravascular ultrasound of coronary arteries in children. Assessment of the wall morphology and the lumen after Kawasaki disease. Circulation 89:258–265PubMedCrossRefGoogle Scholar
  17. 17.
    Niboshi A, Hamaoka K, Sakata K, Yamaguchi N (2008) Endothelial dysfunction in adult patients with a history of Kawasaki disease. Eur J Pediatr 167:189–196PubMedCrossRefGoogle Scholar
  18. 18.
    Takahashi K, Oharaseki T, Naoe S (2001) Pathological study of postcoronary arteritis in adolescents and young adults: with reference to the relationship between sequelae of Kawasaki disease and atherosclerosis. Pediatr Cardiol 22:138–142PubMedCrossRefGoogle Scholar
  19. 19.
    Ross R (1999) Atherosclerosis—an inflammatory disease. N Engl J Med 340:115–126PubMedCrossRefGoogle Scholar
  20. 20.
    Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL (1989) Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 320:915–924PubMedCrossRefGoogle Scholar
  21. 21.
    Niboshi A, Hamaoka K (2006) Recent advances in free radical biology and medicine—oxidative stress and vascular injury of Kawasaki disease. J Clin Exp Med (Tokyo) 64:265–269 (in Japanese)Google Scholar
  22. 22.
    Liu Y, Onouchi Z, Sakata K, Ikuta K (1996) An experimental study on the role of smooth muscle cells in the pathogenesis of atherosclerosis of the coronary arteritis. J Jpn Pediatr Soc 100:1453–1458 (in Japanese)Google Scholar
  23. 23.
    Bruno RS, Pernomian L, Bendhack LM (2012) Contribution of oxidative stress to endothelial dysfunction in hypertension. Front Physiol 3:441CrossRefGoogle Scholar
  24. 24.
    Stephens JW, Khanolkar MP, Bain SC (2009) The biological relevance and measurement of plasma markers of oxidative stress in diabetes and cardiovascular disease. Atherosclerosis 202:321–329PubMedCrossRefGoogle Scholar
  25. 25.
    Araujo FB, Barbosa DS, Hsin CY, Maranhao RC, Abdalla DS (1995) Evaluation of oxidative stress in patients with hyperlipidemia. Atherosclerosis 117:61–71PubMedCrossRefGoogle Scholar
  26. 26.
    Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I (2004) Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 114:1752–1761PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Morrow JD, Frei B, Longmire AW, Gaziano JM, Lynch SM, Shyr Y, Strauss WE, Oates JA, Roberts LJ 2nd (1995) Increased in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med 332:1198–1203PubMedCrossRefGoogle Scholar
  28. 28.
    Ferrieres J (2004) The French paradox: lessons for other countries. Heart 90:170–211CrossRefGoogle Scholar
  29. 29.
    Pratlco D, Tangirala RK, Rader DJ, Rokach J, FitzGerald GA (1998) Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice. Nat Med 4:1189–1192CrossRefGoogle Scholar
  30. 30.
    Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C (2007) Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systemic review and meta-analysis. JAMA 297:842–857PubMedCrossRefGoogle Scholar
  31. 31.
    Baillie JK, Thompson AA, Irving JB, Bates MG, Sutherland AI, Macnee W, Maxwell SR, Webb DJ (2009) Oral antioxidant supplementation does not prevent acute mountain sickness: double blind, randomized placebo-controlled trial. QJM 102:341–348PubMedCrossRefGoogle Scholar
  32. 32.
    Griendling KK, FitzGerald GA (2003) Oxidative stress and cardiovascular injury part 1: basic mechanisms and in vivo monitoring of ROS. Circulation 108:1912–1916PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2014

Authors and Affiliations

  1. 1.Department of Pediatric Cardiology and Nephrology, Graduate School of Medical ScienceKyoto Prefectural University of MedicineKyotoJapan

Personalised recommendations